Clinical Trials Directory

Trials / Completed

CompletedNCT06104293

Determination of Grass Pollen Allergen Concentration Inducing Rhinoconjunctivitis Symptoms in Subjects Allergic to Grass Pollen in ALYATEC Allergen Exposure Chamber

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
24 (actual)
Sponsor
Alyatec · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to determine the optimal concentration of grass pollen allergens inducing rhinoconjunctivitis in subjects allergic to grass pollen in ALYATEC allergen exposure chamber. Four concentrations of grass pollen allergen (Phl p 5) are tested during 3-hour exposures: 0, 30, 60 and 90 ng/m3.

Conditions

Interventions

TypeNameDescription
OTHERGrass Pollen Allergen ExposureAfter the screening visit, subjects are randomized into 3 groups presenting a sequence of allergen concentrations with randomly defined concentrations of Ph l p 5 (0, 30, 60 and 90 ng/m3). Each participant undergo four different 3-hour exposure sessions to grass pollen allergen corresponding to the four different allergen concentrations.

Timeline

Start date
2022-11-16
Primary completion
2023-02-07
Completion
2023-04-06
First posted
2023-10-27
Last updated
2023-11-27

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT06104293. Inclusion in this directory is not an endorsement.